Systemic therapy of corticosteroids and immunosuppressants better preserved vision in patients with uveitis compared to Bausch & Lomb‘s long-lasting corticosteroid intraocular implant in a clinical trial supported by the National Eye Institute, a branch of the National Institutes of Health.
In 7 years, visual acuity remained stable in patients receiving systemic therapy and declined by an average of 1 line on an eye chart among patients with the implant, according to the study.
Get the full story at our sister site, Drug Delivery Business News.